Get notified when YDES files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Red Flags Detected

  • Going Concern (new) — The company explicitly states substantial doubt about its ability to continue as a going concern for at least twelve months.
  • Concentration of Customers (new) — A single customer order accounted for 39% of revenue, and customer B represented 48.6% of sales, indicating heavy reliance on one customer.
  • Concentration of Suppliers (new) — Two suppliers accounted for over 62% of purchases, and the CEO holds a significant stake in a major supplier, creating related-party risk.
NASDAQ: YDES YD Bio Ltd 424B3

YD Bio Ltd files 424B3 prospectus; Taiwan biopharma formed via reverse recapitalization, no offering terms disclosed

Filed September 1, 2026 · ~1 min read

Key Changes

  • high

    YD Bio Ltd, a Taiwan-based biopharmaceutical company formed through a reverse recapitalization of Breeze Holdings, filed a 424B3 prospectus; the filing does not disclose offering size or price.

    The Offering view on EDGAR →
  • high

    The company reported a GAAP net loss of $3.1 million for the six months ended June 30, 2026, up from $1.9 million a year earlier, with an accumulated deficit of $10.2 million.

    Management's Discussion and Analysis verify on EDGAR →
  • high

    Revenue grew 315% to $0.8 million, but a single customer order for Fetroja for Injection accounted for 39% of net revenue, and customer B represented 48.6% of sales.

    Management's Discussion and Analysis verify on EDGAR →

2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (CBRL 10-K) is open in full — no account needed.

Partner

Trade YDES commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov

Figures/quotes linked to EDGAR · Narrative written by AI · Sep 1, 2026 · How we verify